dc.contributor.author |
Kenmogne, VL
|
|
dc.contributor.author |
Takalani, AMT
|
|
dc.contributor.author |
Nweke, EE
|
|
dc.contributor.author |
Takundwa, Mutsa M
|
|
dc.contributor.author |
Fabian, June
|
|
dc.contributor.author |
Maher, Heather
|
|
dc.contributor.author |
Du Toit, Justin
|
|
dc.contributor.author |
Philip-Cherian, V
|
|
dc.contributor.author |
Fru, PF
|
|
dc.contributor.author |
Govindaraj, DBT
|
|
dc.date.accessioned |
2023-12-11T07:52:04Z |
|
dc.date.available |
2023-12-11T07:52:04Z |
|
dc.date.issued |
2023-10 |
|
dc.identifier.citation |
Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M.M., Fabian, J., Maher, H., Du Toit, J. & Philip-Cherian, V. et al. 2023. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. <i>Hematology, Transfusion and Cell Therapy, 45(3).</i> http://hdl.handle.net/10204/13383 |
en_ZA |
dc.identifier.issn |
2531-1379 |
|
dc.identifier.issn |
2531-1387 |
|
dc.identifier.uri |
https://doi.org/10.1016/j.htct.2023.09.053
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/13383
|
|
dc.description.abstract |
Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept. |
en_US |
dc.format |
Fulltext |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://www.sciencedirect.com/science/article/pii/S2531137923002298 |
en_US |
dc.source |
Hematology, Transfusion and Cell Therapy, 45(3) |
en_US |
dc.subject |
Drug sensitivity |
en_US |
dc.subject |
Ex vivo |
en_US |
dc.subject |
Leukaemia |
en_US |
dc.subject |
Myeloma |
en_US |
dc.subject |
Patient cohort |
en_US |
dc.title |
Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
S32-S33 |
en_US |
dc.description.note |
Article published under a Creative Commons license. |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Synthetic Nanobiotech Biomachs |
en_US |
dc.identifier.apacitation |
Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M. M., Fabian, J., Maher, H., ... Govindaraj, D. (2023). Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. <i>Hematology, Transfusion and Cell Therapy, 45(3)</i>, http://hdl.handle.net/10204/13383 |
en_ZA |
dc.identifier.chicagocitation |
Kenmogne, VL, AMT Takalani, EE Nweke, Mutsa M Takundwa, June Fabian, Heather Maher, Justin Du Toit, V Philip-Cherian, PF Fru, and DBT Govindaraj "Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort." <i>Hematology, Transfusion and Cell Therapy, 45(3)</i> (2023) http://hdl.handle.net/10204/13383 |
en_ZA |
dc.identifier.vancouvercitation |
Kenmogne V, Takalani A, Nweke E, Takundwa MM, Fabian J, Maher H, et al. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3). 2023; http://hdl.handle.net/10204/13383. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Kenmogne, VL
AU - Takalani, AMT
AU - Nweke, EE
AU - Takundwa, Mutsa M
AU - Fabian, June
AU - Maher, Heather
AU - Du Toit, Justin
AU - Philip-Cherian, V
AU - Fru, PF
AU - Govindaraj, DBT
AB - Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept.
DA - 2023-10
DB - ResearchSpace
DP - CSIR
J1 - Hematology, Transfusion and Cell Therapy, 45(3)
KW - Drug sensitivity
KW - Ex vivo
KW - Leukaemia
KW - Myeloma
KW - Patient cohort
LK - https://researchspace.csir.co.za
PY - 2023
SM - 2531-1379
SM - 2531-1387
T1 - Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort
TI - Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort
UR - http://hdl.handle.net/10204/13383
ER -
|
en_ZA |
dc.identifier.worklist |
27195 |
en_US |